Muscarinic M1 receptor agonists and M2 receptor antagonists as therapeutic targets in Alzheimer's disease

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 6, 2002, Pages 863-870

  Sheardown, Malcolm J ^a  

^a Vernalis PLC   (United Kingdom)

Author keywords

Acetylcholine; Alzheimer's disease; M1 receptor agonists; M2 receptor antagonists; Muscarinic receptors

Indexed keywords

1 (4 CYCLOHEXYL 2 METHYLPIPERAZINO) 5 (4 METHOXYPHENYLSULFONYL) 1H INDANE; 2 ARYLETHYL (PIPERIDINE 4 YLMETHYL)AMINE DERIVATIVE; 4 CYANO[4 (3 METHYLENEDIOXYPHENYLSULFONYL)PHENYL]AMINO 1 CYCLOXYHEXYLPIPERIDINE; 4 CYCLOHEXYL ALPHA [4 [(4 METHOXYPHENYL)SULFINYL]PHENYL] 1 PIPERAZINEACETONITRILE; 5H DIBENZI[B,F]AZEPINE DERIVATIVE; ACETYLCHOLINE; ALVAMELINE; AMYLOID BETA PROTEIN; CEVIMELINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; G PROTEIN COUPLED RECEPTOR; GALANTAMINE; MILAMELINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M2 RECEPTOR; MUSCARINIC M2 RECEPTOR ANTAGONIST; MUSCARINIC M3 RECEPTOR; OTENZEPAD; PIPERIDINE DERIVATIVE; PYRIDAZINO [4,5 B] INDOLIZINE DERIVATIVE; RIVASTIGMINE; SABCOMELINE; SCH 217443; SCH 72788; TACRINE; TILSACLIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANOMELINE;

ALZHEIMER DISEASE; CARDIOTOXICITY; CATABOLISM; CELL LOSS; CHOLINERGIC NERVE CELL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; GASTROINTESTINAL TOXICITY; HUMAN; NEOCORTEX; NONHUMAN; PATENT; REVIEW; SALIVATION; SENILE DEMENTIA;

EID: 0036078699     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.6.863     Document Type: Review

References (37)

1. Age-specific incidence of Alzheimer-related changes
2. The basis for behavioural disturbances in dementia
3. Neurotransmitter related enzymes and indices of hypoxia in senile dementia and other abiotrophies
4. Selective loss of central cholinergic neurones in Alzheimer's disease
5. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue
6. Alzheimer's disease and senile dementia: Loss of neurones in basal forebrain
7. Evidence for high affinity choline transport in synaptosomes prepared from hippocampus and neocortex of patients with Alzheimer's disease
8. Physostigmine restores [3H]-acetylcholine efflux from Alzheimer brain slices to normal level
9. Human memory and the cholinergic system
10. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease; investigative and therapeutic perspectives
11. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia
12. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities
13. Pre-synaptic cholinergic dysfunction in patients with dementia
14. Reduction in acetylcholine and nicotine binding in several degenerative diseases
15. Nicotinic and muscarinic subtypes in the human brain: Changes with aging and dementia
16. Muscarinic receptors - Characterisation, coupling and function
17. The muscarinic M 1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese Hamster Ovary - M1 cells
18. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease
19. Reduction of cerebrospinal fluid amyloid β after systemic administration of M1 muscarinic agonists
20. Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospina; fluid levels of total amyloid β-peptide in patients with Alzheimer's disease
21. The selective muscarinic M1 agonist AF102B decreases levels of total Aβ in cerebrospinal fluid of patients with Alzheimer's disease
22. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioural symptoms in Alzheimer's disease
23. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease: Rationale and perspectives
24. Identification, localisation and classification of muscarinic receptor subtypes in the gut
25. SDZ ENS 163, a novel pilocarpine-like drug: Pharmacological in vitro and in vivo profile
26. Biochemical and behavioural evidence for muscarinic autoreceptors in the CNS
27. The autoinhibitory feedback control of acetylcholine release in human neocortex tissue
28. 2 receptor antagonist AF-DX 116 improves memory
29. Muscarinic agonists and antagonists in the treatment of Alzheimer's disease
30. Lu 25-109, a muscarinic agonist fails to improve cognition in Alzheimer's disease
31. Facilitation of acetylcholine release and improvement in cognition by a selective M2 musacarinic antagonist, SCH 72788
32. Pharmacology of muscarinic acetylcholine receptor subtypes (m1-m5): High throughput assays in mammalian cells
33. 4 muscarinic receptor subtypes in Alzheimer's disease
34. Elucidating the role of muscarinic receptors in psychosis
35. Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain
36. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PD-APP mouse
37. (+/-)Cis-2-methylspiro[1,3-oxathiolane-5,3′-quinuclidine] hydrochloride, hemihydrate (SN-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: The role of muscarinic acetylcholine receptors